Screener
BioMarin Pharmaceuticals BMRN Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| ASSETS | June 30, 2026 / (unaudited) | December 31, 2025 ⁽¹⁾ |
|---|---|---|
| Stockholders’ equity: | ||
| Common stock, $0.001 par value: 500,000,000 shares authorized; 193,535,556 and 192,300,101 shares issued and outstanding, respectively | 194 | 192 |
| Additional paid-in capital | 6,037,019 | 5,956,582 |
| Company common stock held by the Nonqualified Deferred Compensation Plan | (11,233) | (10,508) |
| Accumulated other comprehensive loss | (8,783) | (13,473) |
| Retained earnings | 304,495 | 154,206 |
| Total stockholders’ equity | 6,321,692 | 6,086,999 |
| Total liabilities and stockholders’ equity | $11,723,442 | $7,594,022 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's retained earnings?
- BioMarin Pharmaceuticals (BMRN) reported retained earnings of $304.5M in Q2 2026.
- How has BioMarin Pharmaceuticals's retained earnings changed year-over-year?
- BioMarin Pharmaceuticals's retained earnings increased by 31.5% year-over-year, from $231.52M to $304.5M.
- What is the long-term trend for BioMarin Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's retained earnings has grown at a -29.1% compound annual growth rate (CAGR), from -$861.61M to $154.21M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about BioMarin Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude